Raziye Akcılar1, Sebahat Turgut2, Vildan Caner3, Aydın Akcılar4, Ceylan Ayada5, Levent Elmas3, T Olgun Özcan2. 1. University of Dumlupınar, Faculty of Medicine, Department of Physiology, Kütahya, Turkey. Electronic address: raziyeakcilar@gmail.com. 2. University of Pamukkale, Faculty of Medicine, Department of Physiology, Denizli, Turkey. 3. University of Pamukkale, Faculty of Medicine, Department of Medical Biology, Denizli, Turkey. 4. University of Dumlupınar, Faculty of Medicine, Kütahya, Turkey. 5. University of Dumlupınar, Faculty of Medicine, Department of Physiology, Kütahya, Turkey.
Abstract
PURPOSE: Apelin is an adipokine that plays a role in the regulation of many biological functions in mammals including the neuroendocrine, cardiovascular, immune systems, glucose homeostasis and obesity. It can act via autocrine, paracrine, endocrine, and exocrine signaling. We aimed to identify the role of apelin pathophysiology of diabetes. MATERIAL/ METHODS: 37 male Wistar Albino rats aged 8-10 weeks were divided in four experimental groups as: control group (C) control+apelin group (C+A), diabetic group (D) diabetic+apelin group (D+A). Apelin and apelin receptor mRNA gene expressions in heart and aorta tissue were determined by real-time polymerase chain reaction. The plasma levels of insulin and plasma apelin were determined by ELISA. RESULTS: Plasma levels of insulin, glucose, blood pressure levels were significantly lower in D+A group. There was no statistically significant difference for level of apelin between diabetic groups. On the other hand, differences for apelin and APJ mRNA expression in heart and vascular tissue were found significant between groups. CONCLUSIONS: Apelin can be used as a therapeutic agent in the treatment of type II diabetes in the future.
PURPOSE:Apelin is an adipokine that plays a role in the regulation of many biological functions in mammals including the neuroendocrine, cardiovascular, immune systems, glucose homeostasis and obesity. It can act via autocrine, paracrine, endocrine, and exocrine signaling. We aimed to identify the role of apelin pathophysiology of diabetes. MATERIAL/ METHODS: 37 male Wistar Albino rats aged 8-10 weeks were divided in four experimental groups as: control group (C) control+apelin group (C+A), diabetic group (D) diabetic+apelin group (D+A). Apelin and apelin receptor mRNA gene expressions in heart and aorta tissue were determined by real-time polymerase chain reaction. The plasma levels of insulin and plasma apelin were determined by ELISA. RESULTS: Plasma levels of insulin, glucose, blood pressure levels were significantly lower in D+A group. There was no statistically significant difference for level of apelin between diabetic groups. On the other hand, differences for apelin and APJ mRNA expression in heart and vascular tissue were found significant between groups. CONCLUSIONS:Apelin can be used as a therapeutic agent in the treatment of type II diabetes in the future.
Authors: Andrea Gila-Diaz; Silvia M Arribas; Alba Algara; María A Martín-Cabrejas; Ángel Luis López de Pablo; Miguel Sáenz de Pipaón; David Ramiro-Cortijo Journal: Nutrients Date: 2019-06-10 Impact factor: 5.717
Authors: Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport Journal: Pharmacol Rev Date: 2019-10 Impact factor: 25.468